130403-93-9

Basic information

• Product Name: (S)-benzyl 3-acetoxypyrrolidine-1-carboxylate
• Synonyms: (S)-benzyl 3-acetoxypyrrolidine-1-carboxylate
• CAS NO: 130403-93-9
• Molecular Weight: 263.293
• Mol File: 130403-93-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (S)-benzyl 3-acetoxypyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-benzyl 3-acetoxypyrrolidine-1-carboxylate(130403-93-9)
• EPA Substance Registry System: (S)-benzyl 3-acetoxypyrrolidine-1-carboxylate(130403-93-9)

Safety Data

• Hazardous Substances Data: 130403-93-9(Hazardous Substances Data)

Upstream product

• 108-24-7 acetic anhydride 
• 100858-32-0 (S)-3-hydroxy-1-pyrrolidinecarboxylic acid phenylmethyl ester 
• 174621-88-6 (S)-3-(acetyloxy)-1-pyrrolidinecarboxylic acid, phenylmethyl ester 
• 64-19-7 acetic acid 
• 100858-33-1 (3R)-3-hydroxy-pyrrolidine-1-carboxylic acid benzyl ester 
• 1972-28-7 diethylazodicarboxylate 
• 95656-88-5 benzyl 3-hydroxypyrrolidine-1-carboxylate 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 100858-32-0 (S)-3-hydroxy-1-pyrrolidinecarboxylic acid phenylmethyl ester 
• 130403-94-0 (S)-(pyrrolidin-3-yl) acetate 
• 163457-21-4 (R)-benzyl 3-fluoropyrrolidine-1-carboxylate 

Relevant articles and documents

PROTEIN KINASE INHIBITOR PRODRUGS

The present invention relates to ester and phosphate prodrugs of the protein kinase inhibitor N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-((S)-3-hydroxypyrrolidin-1- yl)pyrimidin4-yl]amino]thiazole-5-carboxarnide (compound X), stereoisomers, isomeric mixtures including racemic mixtures, and/or 4-deutero substituted derivatives thereof.

CYCLOHEXYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel cyclohexylalanine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors

Amides derived from fluorinated pyrrolidines and 4-substituted cyclohexylglycine analogues have been prepared and evaluated as inhibitors of dipeptidyl dipeptidase IV (DP-IV). Analogues which incorporated (S)-3-fluoropyrrolidine showed good selectivity for DP-IV over quiescent cell proline dipeptidase (QPP). Compound 48 had good pharmacokinetic properties and was orally active in an oral glucose tolerance test in lean mice.